FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807888054> ?p ?o ?g. }

• W2807888054 abstract "Background Rheumatoid arthritis (RA) causes high individual, medical and societal costs. EULAR guidelines suggest treating early, intensively and to target using disease modifying anti-rheumatic drugs (DMARDs), preferably with initial glucocorticoid (GC) bridging. COBRA slim, a combination of methotrexate (MTX) with a moderate dose prednisone step down bridge scheme showed a positive efficacy/tolerability balance in the Care in early RA (CareRA) trial. COBRA Slim in comparison to DMARD combination therapy with GC bridging, has the necessary intensity to induce remission, but with a lower risk of severe discomfort or adverse events, decreasing the early need for biologic (b)DMARDs. Objectives Perform an economic evaluation on the 2 year pragmatic randomised CareRA trial. Methods Patients with early RA (≤1 year) naive to DMARDs were randomised to monotherapy or synthetic (cs)DMARD combination with or without GC bridging, after risk stratification based on classical prognostic markers. Clinical and patient-reported data were collected at each visit (≥10 times in 2 years). Direct costs of visits and RA medication (systemic GCs, cs and bDMARDs) over 2 years were calculated for each patient from each of the 5 treatment arms (table 1). For cost-effectiveness analysis, benefits were expressed as the proportion of patients with DAS28CRP For cost-utility analysis, utilities were calculated using a validated mapping algorithm reconstructing EQ-5D scores based on age, sex, HAQ and pain scores at relevant study visits. Quality-adjusted life years (QALYs) encapsulating the impact of treatment on a patient’s length of life and health-related quality of life, were calculated as the time-weighted average of all available EQ-5D scores (area under the curve). Incremental cost-effectiveness ratios (ICERs) from each strategy were calculated. ICERs compare the additional costs a strategy imposes over another with the additional benefits it delivers. Means and medians based methods were calculated with confidence intervals via bootstrapping. Results From the initial CareRA cohort (n=379),cost/benefit data of 326 patients was used for a 2 year economic analysis. The mayor driver of direct costs was bDMARDs (57%>87% of total costs). Number of consultations were comparable (±11) across all treatment strategies. The cost-effectiveness analysis in the high risk population showed a higher ICER for COBRA Avant Garde (mean €198.65/1%, median €78.41/1%) and a dominated ICER for COBRA Classic (mean €-181.40/1%, median €-35.01/1%) compared to the Slim. In the low risk arm, ICERs for COBRA Slim compared to Tight Step Up (TSU) were €46.75/1% (mean) and €43.64/1% (median). Cost-utility analysis in the high risk arm showed an incremental cost of €1 469.36 for an increased utility of 0.012555 QALYS for COBRA Classic compared to COBRA Slim, resulting in an ICER of €117 033.85/QALY. The ICER of COBRA Avant Garde vs COBRA Slim was €69 329.19/QALY. In the low risk arm, the comparison of COBRA Slim to TSU yields an ICER of €1 342.78 per QALY. Conclusions COBRA Slim which consists of an initial combination of MTX and a moderate dosed GC remission induction scheme has a favourable cost-effective and cost-utility profile for patients with early RA independent of their prognostic factors. Disclosure of Interest S. Pazmino: None declared, R. Westhovens: None declared, J. Joly: None declared, V. Stouten: None declared, D. De Cock: None declared, K. Van der Elst: None declared, P. Verschueren Grant/research support from: Unrestricted Pfizer Chair in the management of early rheumatoid arthritis" @default.
• W2807888054 created "2018-06-21" @default.
• W2807888054 creator A5003304778 @default.
• W2807888054 creator A5006123817 @default.
• W2807888054 creator A5043961611 @default.
• W2807888054 creator A5046660631 @default.
• W2807888054 creator A5055647749 @default.
• W2807888054 creator A5081949747 @default.
• W2807888054 creator A5090277186 @default.
• W2807888054 date "2018-06-01" @default.
• W2807888054 modified "2023-10-18" @default.
• W2807888054 title "OP0301 Two year cost-effectiveness analysis of the carera trial in early ra: a piggy back study" @default.
• W2807888054 doi "https://doi.org/10.1136/annrheumdis-2018-eular.7296" @default.
• W2807888054 hasPublicationYear "2018" @default.
• W2807888054 type Work @default.
• W2807888054 sameAs 2807888054 @default.
• W2807888054 citedByCount "0" @default.
• W2807888054 crossrefType "proceedings-article" @default.
• W2807888054 hasAuthorship W2807888054A5003304778 @default.
• W2807888054 hasAuthorship W2807888054A5006123817 @default.
• W2807888054 hasAuthorship W2807888054A5043961611 @default.
• W2807888054 hasAuthorship W2807888054A5046660631 @default.
• W2807888054 hasAuthorship W2807888054A5055647749 @default.
• W2807888054 hasAuthorship W2807888054A5081949747 @default.
• W2807888054 hasAuthorship W2807888054A5090277186 @default.
• W2807888054 hasBestOaLocation W28078880541 @default.
• W2807888054 hasConcept C112930515 @default.
• W2807888054 hasConcept C126322002 @default.
• W2807888054 hasConcept C159110408 @default.
• W2807888054 hasConcept C168563851 @default.
• W2807888054 hasConcept C1862650 @default.
• W2807888054 hasConcept C197934379 @default.
• W2807888054 hasConcept C2777575956 @default.
• W2807888054 hasConcept C2778375690 @default.
• W2807888054 hasConcept C2778720950 @default.
• W2807888054 hasConcept C2779951463 @default.
• W2807888054 hasConcept C3019080777 @default.
• W2807888054 hasConcept C64332521 @default.
• W2807888054 hasConcept C71924100 @default.
• W2807888054 hasConceptScore W2807888054C112930515 @default.
• W2807888054 hasConceptScore W2807888054C126322002 @default.
• W2807888054 hasConceptScore W2807888054C159110408 @default.
• W2807888054 hasConceptScore W2807888054C168563851 @default.
• W2807888054 hasConceptScore W2807888054C1862650 @default.
• W2807888054 hasConceptScore W2807888054C197934379 @default.
• W2807888054 hasConceptScore W2807888054C2777575956 @default.
• W2807888054 hasConceptScore W2807888054C2778375690 @default.
• W2807888054 hasConceptScore W2807888054C2778720950 @default.
• W2807888054 hasConceptScore W2807888054C2779951463 @default.
• W2807888054 hasConceptScore W2807888054C3019080777 @default.
• W2807888054 hasConceptScore W2807888054C64332521 @default.
• W2807888054 hasConceptScore W2807888054C71924100 @default.
• W2807888054 hasLocation W28078880541 @default.
• W2807888054 hasOpenAccess W2807888054 @default.
• W2807888054 hasPrimaryLocation W28078880541 @default.
• W2807888054 hasRelatedWork W1434172106 @default.
• W2807888054 hasRelatedWork W1988152642 @default.
• W2807888054 hasRelatedWork W2006622771 @default.
• W2807888054 hasRelatedWork W2328285503 @default.
• W2807888054 hasRelatedWork W2328681720 @default.
• W2807888054 hasRelatedWork W2334522246 @default.
• W2807888054 hasRelatedWork W2411232801 @default.
• W2807888054 hasRelatedWork W2507844178 @default.
• W2807888054 hasRelatedWork W2552882555 @default.
• W2807888054 hasRelatedWork W2568765207 @default.
• W2807888054 hasRelatedWork W2767195381 @default.
• W2807888054 hasRelatedWork W2808661438 @default.
• W2807888054 hasRelatedWork W2902140242 @default.
• W2807888054 hasRelatedWork W2911714458 @default.
• W2807888054 hasRelatedWork W2946098156 @default.
• W2807888054 hasRelatedWork W3014494660 @default.
• W2807888054 hasRelatedWork W3046644084 @default.
• W2807888054 hasRelatedWork W3122050683 @default.
• W2807888054 hasRelatedWork W3138030179 @default.
• W2807888054 hasRelatedWork W3154649715 @default.
• W2807888054 isParatext "false" @default.
• W2807888054 isRetracted "false" @default.
• W2807888054 magId "2807888054" @default.
• W2807888054 workType "article" @default.